Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice

Inhibition of myostatin is a promising strategy for treatment of muscle atrophic disorders. We had already identified a 23mer peptide (1) as a synthetic myostatin inhibitor, and structure activity relationship studies with 1 afforded a potent 22-mer peptide derivative (3). Herein, we report the shortest myostatin inhibitory peptide so far. Among chain-shortened 16-mer peptidic inhibitors derived from the C-terminal region of 3, peptide inhibitor 8a with beta-sheet propensity was twice as potent as 22-mer inhibitor 3 and significantly increased not only muscle mass but also hind limb grip strength in Duchenne muscular dystrophic model mice. These results suggest that 8a is a promising platform for drug development treating muscle atrophic disorders.